Abstract： Objective： To observe the efficacy of Houtou Jianweiling Capsules assisted proton pump inhibitor quadruple therapy in treating Helicobacter pylori （Hp）-positive erosive gastritis of liver-stomach disharmony type and its impact on immune function. Methods： Clinical data of 140 patients with Hp-positive erosive gastritis of liverstomach disharmony type admitted to Zhejiang Jinhua Guangfu Tumor Hospital from June 2023 to June 2024 were retrospectively analyzed. Patients were divided into a control group and an observation group according to the treatment protocol，with 70 cases in each group. The control group received proton pump inhibitor quadruple therapy，while the observation group received Houtou Jianweiling Capsules assisted proton pump inhibitor quadruple therapy. Both groups were treated for two weeks. Clinical symptom scores， gastric mucosal erosion scores， gastric function indicators [gastrin-17（ G-17），pepsinogenⅠ（PGⅠ），pepsinogenⅡ（PGⅡ）]，and immune function indicators（ CD3+，CD4+， CD8+ ， CD4+/CD8+ ratio） before and after treatment were compared. Clinical efficacy， Hp eradication rates， and incidence of adverse reactions were compared between the two groups. Results：After treatment，the total effective rate was higher in the observation group than in the control group （P＜0.05）. Epigastric pain，poor appetite，acid reflux， belching，and abdominal distension scores decreased in both groups after treatment （P＜0.05），with lower scores in the observation group （P＜0.05）. Gastric mucosal erosion scores and serum PGⅡ levels decreased，serum G-17 and PGⅠ levels increased in both groups after treatment （P＜0.05）. The observation group showed lower gastric mucosal erosion scores and serum PGⅡ levels ，higher serum G-17 and PGⅠ levels than the control group （P＜0.05）. CD3+， CD4+ levels，and CD4+/CD8+ ratio increased，while CD8+ levels decreased in both groups after treatment （P＜0.05）. The observation group had higher CD3+ and CD4+ levels， higher CD4+/CD8+ ratio， and lower CD8+ levels than the control group （P＜0.05）. There was no statistically significant difference in the incidence of adverse reactions between the two groups （P＞0.05）. The Hp eradication rates at three months and six months after treatment were higher in the observation group than in the control group （P＜0.05）. Conclusion： Houtou Jianweiling Capsules assisted proton pump inhibitor quadruple therapy effectively alleviates clinical symptoms， improves Hp eradication rates， and exerts immunomodulatory effects in patients with Hp-positive erosive gastritis of liver-stomach disharmony type.